Acceptance of emerging renal oncocytic neoplasms: a survey of urologic pathologists

Sambit K. Mohanty(Advanced Medical Research Institute), Anandi Lobo(All India Institute of Medical Sciences Raipur), Shilpy Jha(Advanced Medical Research Institute), Ankur R. Sangoi(El Camino Hospital), Mahmut Akgül(Albany Medical Center Hospital), Kiril Trpkov(University of Calgary), Ondřej Hes(Biopticka Laborator (Czechia)), Rohit Mehra(University of Michigan), Michelle S. Hirsch(Brigham and Women's Hospital), Holger Moch(University Hospital of Zurich), Steven C. Smith(Virginia Commonwealth University), Rajal B. Shah(Southwestern Medical Center), Liang Cheng(Brown University), Mahul B. Amin(University of Tennessee Health Science Center), Jonathan I. Epstein(Garden City Community College), Anil V. Parwani(The Ohio State University), Brett Delahunt(Wellington Hospital), Sangeeta Desai(Tata Memorial Hospital), Christopher G. Przybycin(Cleveland Clinic), Claudia Manini(University of Turin), Daniel Luthringer(Cedars-Sinai Medical Center), Deepika Sirohi(ARUP Laboratories (United States)), Deepika Jain, Divya Midha(Tata Medical Center), Ekta Jain, Fiona Maclean(Douglass Hanly Moir Pathology), Giovanna A. Giannico(Vanderbilt University Medical Center), Gladell P. Paner(University of Chicago), Guido Martignoni(University of Verona), Hikmat Al‐Ahmadie(Memorial Sloan Kettering Cancer Center), Jesse K. McKenney(Cleveland Clinic), John R. Srigley(Credit Valley Hospital), José I. López(Hospital de Cruces), Lakshmi P. Kunju(University of Michigan), Lisa Browning(Oxford Health NHS Foundation Trust), Manju Aron(Keck Hospital of USC), Maria M. Picken(Loyola University Medical Center), Maria Tretiakova(University of Washington), Ming Zhou(Boston University), Mukund Sable(All India Institute of Medical Sciences Bhubaneswar), Naoto Kuroda(Japanese Red Cross Kochi Hospital), Niharika Pattnaik(Advanced Medical Research Institute), Nilesh Gupta(Henry Ford Health System), Priya Rao(The University of Texas MD Anderson Cancer Center), Samson W. Fine(Memorial Sloan Kettering Cancer Center), Pritinanda Mishra(All India Institute of Medical Sciences Bhubaneswar), Amit Kumar Adhya(All India Institute of Medical Sciences Bhubaneswar), Bijal Kulkarni(Kokilaben Dhirubhai Ambani Hospital), Mallika Dixit, Manas Baisakh(Apollo Hospitals), Samriti Arora, Sankalp Sancheti(Cancer Hospital and Research Institute), Santosh Menon(Tata Memorial Hospital), Sara E. Wobker(University of North Carolina at Chapel Hill), Satish K. Tickoo(Memorial Sloan Kettering Cancer Center), Seema Kaushal(All India Institute of Medical Sciences), Shailesh Soni(Muljibhai Patel Urological Hospital), Shivani Kandukuri(Keck Hospital of USC), Shivani Sharma, Suvradeep Mitra(Post Graduate Institute of Medical Education and Research), Victor E Reuter(Memorial Sloan Kettering Cancer Center), Vipra Malik, Vishal Rao(Basavatarakam Indo American Cancer Hospital and Research Institute), Ying‐Bei Chen(Memorial Sloan Kettering Cancer Center), Sean R. Williamson(Cleveland Clinic)
Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin
September 17, 2024
Cited by 6Open Access
Full Text

Abstract

Oncocytic renal neoplasms are a major source of diagnostic challenge in genitourinary pathology; however, they are typically nonaggressive in general, raising the question of whether distinguishing different subtypes, including emerging entities, is necessary. Emerging entities recently described include eosinophilic solid and cystic renal cell carcinoma (ESC RCC), low-grade oncocytic tumor (LOT), eosinophilic vacuolated tumor (EVT), and papillary renal neoplasm with reverse polarity (PRNRP). A survey was shared among 65 urologic pathologists using SurveyMonkey.com (Survey Monkey, Santa Clara, CA, USA). De-identified and anonymized respondent data were analyzed. Sixty-three participants completed the survey and contributed to the study. Participants were from Asia (n = 21; 35%), North America (n = 31; 52%), Europe (n = 6; 10%), and Australia (n = 2; 3%). Half encounter oncocytic renal neoplasms that are difficult to classify monthly or more frequently. Most (70%) indicated that there is enough evidence to consider ESC RCC as a distinct entity now, whereas there was less certainty for LOT (27%), EVT (29%), and PRNRP (37%). However, when combining the responses for sufficient evidence currently and likely in the future, LOT and EVT yielded > 70% and > 60% for PRNRP. Most (60%) would not render an outright diagnosis of oncocytoma on needle core biopsy. There was a dichotomy in the routine use of immunohistochemistry (IHC) in the evaluation of oncocytoma (yes = 52%; no = 48%). The most utilized IHC markers included keratin 7 and 20, KIT, AMACR, PAX8, CA9, melan A, succinate dehydrogenase (SDH)B, and fumarate hydratase (FH). Genetic techniques used included TSC1/TSC2/MTOR (67%) or TFE3 (74%) genes and pathways; however, the majority reported using these very rarely. Only 40% have encountered low-grade oncocytic renal neoplasms that are deficient for FH. Increasing experience with the spectrum of oncocytic renal neoplasms will likely yield further insights into the most appropriate work-up, classification, and clinical management for these entities.


Related Papers

No related papers found

Powered by citation graph analysis